CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
VELCADEdrug
Likely dose
VELCADE 1.6 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00298766
NCT00298766Phase 2Completed
CompareCT.gov

An Open-Label Phase 1/2 Study of VELCADE for Injection in Subjects With Light-Chain (AL)-Amyloidosis

Millennium Pharmaceuticals, Inc.·interventional·Posted Mar 3, 2006·Updated Jun 25, 2012

In Brief

A Phase 2 clinical trial evaluating VELCADE for Amyloidosis. Completed, enrolled 70 participants across 4 sites.

Detailed Summary

This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with VELCADE in patients with previously treated systemic AL-amyloidosis who require further treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyloidosis
CountriesUnited States
CollaboratorsJohnson & Johnson Pharmaceutical Research & Development, L.L.C.

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 3, 2006
Enrollment StartJun 1, 2005
Primary CompletionJul 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 20.3 years ago

Interventions

VELCADEdrug

Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2 Or Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2